Aitia

Breaking News: Aitia and Servier are expanding their collaboration to tackle one of medicine's biggest challenges: brain cancer. Using Aitia's Gemini Digital Twins technology, which analyzes millions of data points from patient tissues, we aim to discover new treatments for gliomas - tumors that affect over 190,000 people worldwide each year. This marks our fourth collaboration with Servier, building on our existing work in multiple myeloma, pancreatic cancer and Parkinson's disease. Together, we're combining Servier's expertise in drug development with our AI-driven approach to unlock new possibilities for patients. Learn more about this collaboration: ?https://prn.to/4e1MNzK #BrainCancer #DrugDiscovery #AI #DigitalTwins

We’re honored that our CEO and co-founder, Colin Hill, was featured in NYSE’s “We're Cure(ious) About: The Future of Healthcare,”?video series to share his views on data-driven AI approaches to drug discovery and development. Check out the series below and watch Colin’s videos here:?https://lnkd.in/gT_VYeXN ? #AI #DrugDevelopemtn #DigitalTwins

This article by Dr. Rafic Makki of Mubadala Capital nicely lays out two key obstacles for achieving Artificial General Intelligence (AGI) and the transformative impact of AI across several industries. The first is going beyond the “simply bigger” strategy that most of the industry (e.g. NVIDIA, Microsoft, Google, OpenAI, etc.) is focused on towards more clever approaches that are orders of magnitude more efficient such as Liquid AI and?DeepSeek AI. The second is going beyond correlation and pattern finding to discover causal relationships and then running “simulations” of interventions and scenarios beyond the data used to train the models. In addition, causal models require orders of magnitude less data to learn and more efficiently represent the world.? ? Dr. Makki?highlights our company Aitia as an example of causal AI and the corresponding Gemini Digital Twins being applied to the discovery and development of new drugs for diseases from cancers to Alzheimer’s (directly from observational patient data).?Causal AI and Digital Twins allow for the simulation of gene/protein knockdowns to discover novel causal human drug targets that get turned into new drug candidates and the simulation of drugs at the individual patient level to allow for clinical trials to be simulated ahead of the real trial to discover patient populations of responders versus non-responders. With 9 out 10 drugs failing in clinical development and the cost of a drug candidate making it to patients crossing $3 billion, the drug industry desperately needs these solutions. The transformative nature of these causal approaches and Digital Twins in the biopharmaceutical and healthcare industries cannot be overstated given the?very low success rate?and the limitations of doing experiments directly on patients for obvious ethical and financial reasons. This is the next big leap! #AI #DrugDiscovery #DigitalTwins #CausalAI #HealthcareInnovation #BiotechInnovation #ArtificialIntelligence #Pharma #ClinicalTrials #PrecisionMedicine #Biotech #DrugDevelopment #ClinicalTrials #Healthcare

This article by Dr. Rafic Makki of Mubadala Capital nicely lays out two key obstacles for achieving Artificial General Intelligence (AGI) and the transformative impact of AI across several industries. The first is going beyond the “simply bigger” strategy that most of the industry (e.g. NVIDIA, Microsoft, Google, OpenAI, etc.) is focused on towards more clever approaches that are orders of magnitude more efficient such as Liquid AI and?DeepSeek AI. The second is going beyond correlation and pattern finding to discover causal relationships and then running “simulations” of interventions and scenarios beyond the data used to train the models. In addition, causal models require orders of magnitude less data to learn and more efficiently represent the world.? ? Dr. Makki?highlights our company Aitia as an example of causal AI and the corresponding Gemini Digital Twins being applied to the discovery and development of new drugs for diseases from cancers to Alzheimer’s (directly from observational patient data).?Causal AI and Digital Twins allow for the simulation of gene/protein knockdowns to discover novel causal human drug targets that get turned into new drug candidates and the simulation of drugs at the individual patient level to allow for clinical trials to be simulated ahead of the real trial to discover patient populations of responders versus non-responders. With 9 out 10 drugs failing in clinical development and the cost of a drug candidate making it to patients crossing $3 billion, the drug industry desperately needs these solutions. The transformative nature of these causal approaches and Digital Twins in the biopharmaceutical and healthcare industries cannot be overstated given the?very low success rate?and the limitations of doing experiments directly on patients for obvious ethical and financial reasons. This is the next big leap! #AI #DrugDiscovery #DigitalTwins #CausalAI #HealthcareInnovation #BiotechInnovation #ArtificialIntelligence #Pharma #ClinicalTrials #PrecisionMedicine #Biotech #DrugDevelopment #ClinicalTrials #Healthcare

Aitia will be attending J.P. Morgan's Annual Healthcare Conference (#JPM2025) in San Francisco next week - reach out to schedule a meeting with our team to learn more about our work with Gemini Digital Twins and AI for drug discovery and development: [email protected]. Colin Hill Joe Donahue Ruby Hsu Jerome Windsor Jean-Michel Gries #jpm2025, #AI, #drugdiscovery #drugdevelopment #DigitalTwins?

Less than 7% of drugs that enter Phase 1 trials ultimately receive FDA approval. Digital Twins are helping change these odds by enabling researchers to better predict which treatments will succeed in clinical studies. In a recent DIA Global Forum article, our CEO Colin Hill explains how this technology could transform success rates in drug discovery and development and what that means for patients waiting for new treatments. Learn more: https://lnkd.in/gqRnQvuv #AI #DigitalTwins #DrugDevelopment #Medicine #Healthcare

We are honored to partner with Servier to help them advance our understanding of pancreatic cancer and potential treatments through the use of our Digital Twins and Causal AI technology. https://lnkd.in/eHcP-K58 #AI #DigitalTwins #DrugDiscovery #Oncology #PancreaticCancer #CancerResearch

The dramatic decrease in the cost of DNA sequencing, combined with advances in computing power and the emergence of causal AI has made patient-level Digital Twins possible for the first time. Our CEO, Colin Hill, discusses how these technological advances are enabling researchers to test billions of potential treatments virtually before moving to clinical trials in a DIA Global Forum article. Learn how this could speed the discovery and development of new medicines: https://lnkd.in/gqRnQvuv ? #AI #DigitalTwins #DrugDevelopment #Medicine #Healthcare

We are excited to expand our collaboration with Servier to brain cancer. Read more about how we're utilizing Digital Twins and AI to explore new approaches for this indication below. #AI #DigitalTwins #BrainCancer #Oncology

Digital Twins?– computational models of human disease?using real patient data - are already helping reduce clinical trial sizes by up to 33% in Alzheimer's research. This means faster drug development and less reliance on placebo controls. Our CEO, Colin Hill, recently explored how this technology is changing drug discovery and development, from early research through clinical trials for DIA's Global Forum. (Thanks to Medable, Inc's Musaddiq Khan for providing insight as well). Read more: ?https://lnkd.in/gqRnQvuv #AI #DigitalTwins #DrugDevelopment #Medicine #Healthcare